Treatment of Lambert-Eaton myasthenic syndrome with 3,4-diaminopyridin

INTERVENTION: 3,4‐diaminopyridine CONDITION: Lambert‐Eaton myasthenic syndrome PRIMARY OUTCOME: Neurological findings, Barthel Index, compound motor action potentials and waxing rate on nerve conduction studies conducted 1, 2, 4 months after treatment. INCLUSION CRITERIA: 1) Patients who are histopathologically diagnosed as lung cancer. 2) Patients who are electrically diagnosed to have Lambert‐Eaton myasthenic syndrome. 3) Patients who are informed of their diagnosis. 4) Patients who do not have history of seizure or epilepsy. 5) Patients who agreed to participate in the present study by written informed consent.